Baidu
map

J Glob Health:DYSIS-China研究:东北医生对LDL-C控制目标的认知较差

2017-11-01 岱西 中国循环杂志

近期,胡大一等发表了DYSIS-China研究最新分析。该研究显示,患者血脂达标与临床医生对指南推荐的LDL-C控制目标知多少有关,而在我国不同地区、不同级别医院、不同科室、不同职称的医生对此参差不齐。

近期,胡大一等发表了DYSIS-China研究最新分析。该研究显示,患者血脂达标与临床医生对指南推荐的LDL-C控制目标知多少有关,而在我国不同地区、不同级别医院、不同科室、不同职称的医生对此参差不齐。

研究者发现,全国不同地区的医生就LDL-C控制目标的认知程度和患者达标率,差异不小,其中东北地区较低。



图 不同地区的医生中,认为指南所推荐LDL-C控制目标是临床重要参考的比例

在这项研究中,60%以上10年心血管病风险极高危患者(伴有糖尿病或急性冠脉综合征的心血管病患者)和45%以上的高危患者(10年心血管病风险在10%~15%的冠心病患者),LDL-C未能达标。

临床医生对LDL-C控制目标越清晰,患者LDL-C达标率也越高。

研究显示,在所调查的900余位医生中发现,认为指南所推荐LDL-C控制目标是临床重要参考的比例在一级医院的医生中最低,为65.4%,相应患者达标率也最低为47.7%。

另外,在所有调查医生中有74.5%认为,让LDL-C达标很重要,并对83.4%的患者设定了管理目标,但在不同科室中达标率却差异较大在41.5%~66%不等。其中,内分泌科医生反差最大。

在不同地区不同医院中,不同职称的医生也是有所差异,住院医生这方面还需提升。

此外进一步分析可见,一级医院的医生、内分泌科医生以及东北地区的医生所认为的LDL-C控制目标与指南所推荐的一致性也最低。而对LDL-C控制目标了解与指南所推荐保持一致的医生,其接诊患者LDL-C达标率也显着更高(60.4% vs 31.1%)。

研究者指出,这项研究再次强调,临床医生对指南所推荐LDL-C目标的认知是实现患者血脂达标的重要因素。这也提示,基于不同区域、不同级别医院、不同科室和职称的医生要不断强化这方面的认知。

该研究纳入了25317例已服用调脂药物多于3个月的血脂异常患者,患者相应就诊医院级别、接诊医生专业、职称以及患者病史、用药等均记录在案。其中分析了不同级别医院6个科室共926位医生对LDL-C控制目标的掌握程度。


原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2018-07-19 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2017-11-03 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2008121, encodeId=4d2720081213d, content=<a href='/topic/show?id=f244465139' target=_blank style='color:#2F92EE;'>#CHINA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4651, encryptionId=f244465139, topicName=CHINA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Dec 26 10:28:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861170, encodeId=f20a18611e0a0, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 08:28:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422554, encodeId=c46914225543e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601573, encodeId=5ff016015e36c, content=<a href='/topic/show?id=b33956e3501' target=_blank style='color:#2F92EE;'>#控制目标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56735, encryptionId=b33956e3501, topicName=控制目标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec2218881449, createdName=zll0631, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621679, encodeId=b34f16216e9a4, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Fri Nov 03 02:28:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257841, encodeId=4fc625e841ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Wed Nov 01 17:43:06 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2017-11-01 1e127dd4m40(暂无匿称)

    学习了

    0

Baidu
map
Baidu
map
Baidu
map